Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial
- Sponsor
- University Hospital, Rouen
- Study ID
- NCT00213486
- Phase
- PHASE2
- Status
- Completed
Conditions
- Esophageal Neoplasms
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan — DRUG
Study Details
The standard non surgical therapy of locally advanced esophageal cancer is based on a definitive concurrent chemoradiotherapy regimen with fluorouracil and cisplatin. One of the alternative regimen which is being studied is the combination of a weekly cisplatin and irinotecan schedule with radiotherapy. This multicentric phase II clinical trial primarily aimed to evaluate the clinical complete response rate and secondary objectives were toxicity profile and survival.
Key Dates
- Start date
- Jan 15, 2003
- Status verified
- Feb 2026
- Primary completion
- Jun 23, 2006
- Completion
- Jun 23, 2006
Study Design
- Enrollment
- 43 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
clinical complete response defined as no tumor detectable on esophagus endoscopy and no appearance of distant metastasis on CT scan
Related Studies
- Mayo Clinic Upper Digestive Disease SurveyRecruiting · Mayo Clinic · Rochester, Minnesota
- Distribution of Lymph Node Metastases in Esophageal CarcinomaRecruiting · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Houston, Texas
- Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)Recruiting · Universitaire Ziekenhuizen KU Leuven · Houston, Texas
- Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Tucson, Arizona